🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Global Health Concern

Gonorrhoea infections are increasing around the world, with figures suggesting in excess of 82 million infections per year. Particularly high rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs currently available.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring found that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in close succession. This drug, which is also used to treat UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This approval marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

According to data published in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an equal footing with the typical regimen, which involves an injection and a pill. The research enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. Having a single-dose, oral treatment such as this is described as a "revolutionary step" for public health efforts. This is deemed crucial to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.